Advertisement APP Pharma expands Grand Island manufacturing plant - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More

APP Pharma expands Grand Island manufacturing plant

APP Pharmaceuticals, which develops, manufactures and markets injectable pharmaceutical products with a primary focus on the oncology, anti-infective, anesthetic/analgesic and critical care markets, has expanded its Grand Island, New York manufacturing facility by 13,000sqft with $38m investment.

APP Pharma, a wholly subsidiary of Fresenius Kabi Pharmaceuticals, has further added six production lines for injectable products in the plant.

At its Grand Island facility, the company manufactures injectable pharmaceutical products for the North America market that encompasses four therapeutic areas: anti-infectives, critical care, analgesia/anesthesia and oncology.

With this expansion, company intends to hire around 90 employees who will work along with the existing 580 workers currently working on the site.

Fresenius Kabi Science Production & Technology president Michael Schonhofen said the Grand Island facility forms part of a global supply chain network that provides pharmaceutical products to the US and Canada.

"Through the expansion, the site will significantly contribute to the continuous local supply of high quality injectable generics for the US and Canada," Schonhofen said.